Hims & Hers Health, Inc. (HIMS) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Equipment & Services
EV/EBITDA
↓
44.46
↓-27% vs avg
5yr avg: 61.25
30Y Low52.7·High69.8
P/FCF
↑
93.85
↑+55% vs avg
5yr avg: 60.63
30Y Low28.9·High113.4
P/B Ratio
↑
12.83
↑+57% vs avg
5yr avg: 8.16
30Y Low3.7·High15.5
ROE
↑
25.2%
↓+246% vs avg
5yr avg: -17.2%
30Y Low-115%·High31%
Debt/EBITDA
↑
6.36
↑+96% vs avg
5yr avg: 3.25
30Y Low0.1·High6.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HIMS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Hims & Hers Health, Inc. trades at 52.7x earnings, roughly in line with its 5-year average of 54.6x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 138%. On a free-cash-flow basis, the stock trades at 93.8x P/FCF, 55% above the 5-year average of 60.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.9B | $8.4B | $5.7B | $1.9B | $1.3B | $1.2B | $516M | $344M |
| Enterprise Value | $7.8B | $9.3B | $5.5B | $1.8B | $1.3B | $1.2B | $489M | $323M |
| P/E Ratio → | 52.71 | 63.67 | 45.62 | — | — | — | — | — |
| P/S Ratio | 2.96 | 3.57 | 3.88 | 2.14 | 2.49 | 4.50 | 3.47 | 4.17 |
| P/B Ratio | 12.83 | 15.50 | 12.01 | 5.42 | 4.21 | 3.66 | — | — |
| P/FCF | 93.85 | 113.37 | 28.87 | 39.65 | — | — | — | — |
| P/OCF | 23.14 | 27.95 | 22.81 | 25.36 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HIMS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Hims & Hers Health, Inc.'s enterprise value stands at 44.5x EBITDA, 27% below its 5-year average of 61.2x. The Healthcare sector median is 14.1x, placing the stock at a 216% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.95 | 3.74 | 2.04 | 2.41 | 4.26 | 3.29 | 3.91 |
| EV / EBITDA | 44.46 | 52.65 | 69.84 | — | — | — | — | — |
| EV / EBIT | 64.37 | 74.86 | 89.12 | — | — | — | — | — |
| EV / FCF | — | 125.43 | 27.82 | 37.80 | — | — | — | — |
HIMS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Hims & Hers Health, Inc. earns an operating margin of 5.2%. Operating margins have expanded from -3.4% to 5.2% over the past 3 years, signaling improving operational efficiency. ROE of 25.2% indicates solid capital efficiency. ROIC of 10.7% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 79.5% | 82.0% | 77.6% | 75.2% | 73.6% | 54.0% |
| Operating Margin | 5.2% | 5.2% | 4.2% | -3.4% | -13.0% | -42.3% | -10.2% | -90.1% |
| Net Profit Margin | 5.5% | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | -12.2% | -87.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 25.2% | 25.2% | 30.7% | -7.2% | -20.3% | -114.7% | — | — |
| ROA | 9.0% | 9.0% | 21.9% | -5.8% | -16.7% | -39.9% | -19.0% | -100.0% |
| ROIC | 10.7% | 10.7% | 17.7% | -8.4% | -19.1% | -183.4% | — | — |
| ROCE | 10.9% | 10.9% | 14.8% | -8.8% | -20.8% | -51.7% | -19.6% | -144.6% |
HIMS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Hims & Hers Health, Inc. carries a Debt/EBITDA ratio of 6.4x, which is highly leveraged (104% above the sector average of 3.1x). Net debt stands at $892M ($1.1B total debt minus $229M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.07 | 2.07 | 0.02 | 0.03 | 0.02 | 0.02 | — | — |
| Debt / EBITDA | 6.36 | 6.36 | 0.14 | — | — | — | — | — |
| Net Debt / Equity | — | 1.65 | -0.44 | -0.25 | -0.13 | -0.20 | — | — |
| Net Debt / EBITDA | 5.06 | 5.06 | -2.65 | — | — | — | — | — |
| Debt / FCF | — | 12.06 | -1.05 | -1.85 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -1514.40 | -201.66 |
HIMS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.90x means Hims & Hers Health, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.00x to 1.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.90 | 1.90 | 1.79 | 3.00 | 4.52 | 3.41 | 7.43 | 3.38 |
| Quick Ratio | 1.70 | 1.70 | 1.50 | 2.74 | 4.07 | 3.24 | 7.19 | 3.17 |
| Cash Ratio | 1.43 | 1.43 | 1.36 | 2.50 | 3.75 | 3.12 | 6.58 | 2.93 |
| Asset Turnover | — | 1.09 | 2.09 | 1.98 | 1.44 | 0.65 | 1.25 | 1.15 |
| Inventory Turnover | 11.92 | 11.92 | 4.71 | 6.99 | 5.48 | 4.97 | 11.09 | 9.00 |
| Days Sales Outstanding | — | 5.00 | 1.50 | 2.82 | 2.24 | 4.80 | 1.84 | 3.80 |
HIMS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Hims & Hers Health, Inc. returns 1.3% to shareholders annually primarily through share buybacks. The earnings yield of 1.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 1.6% | 2.2% | — | — | — | — | — |
| FCF Yield | 1.1% | 0.9% | 3.5% | 2.5% | — | — | — | — |
| Buyback Yield | 1.3% | 1.1% | 1.5% | 0.1% | 0.0% | 1.8% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.3% | 1.1% | 1.5% | 0.1% | 0.0% | 1.8% | 0.0% | 0.0% |
| Shares Outstanding | — | $258M | $237M | $209M | $205M | $187M | $35M | $35M |
Peer Comparison
Compare HIMS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HIMSYou | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 TDOC | $1B | -6.0 | 14.8 | 4.3 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 DOCS | $5B | 23.1 | 20.8 | 19.4 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 OPRX | $121M | 24.0 | 6.4 | 6.5 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 WELL | $152B | 155.7 | 67.4 | 53.3 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 |
 NVO | $154B | 12.7 | 7.5 | 17.3 | 81.0% | 41.4% | 58.4% | 34.9% | 0.9 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMWL | $119M | -1.2 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 TALK | $869M | 129.8 | 138.1 | — | 43.0% | 1.4% | 6.6% | 3.9% | — |
 GDRX | $712M | 28.6 | 2.9 | 9.3 | 92.8% | 11.0% | 12.3% | 10.6% | 0.3 |
 HCAT | $111M | -0.6 | — | — | 48.7% | -51.7% | -58.3% | -32.9% | — |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See HIMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HIMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HIMS vs TDOC
Side-by-side business, growth, and profitability comparison vs Teladoc Health, Inc..
Start ComparisonHIMS — Frequently Asked Questions
Quick answers to the most common questions about buying HIMS stock.
What is Hims & Hers Health, Inc.'s P/E ratio?
Hims & Hers Health, Inc.'s current P/E ratio is 52.7x. The historical average is 54.6x. This places it at the 50th percentile of its historical range.
What is Hims & Hers Health, Inc.'s EV/EBITDA?
Hims & Hers Health, Inc.'s current EV/EBITDA is 44.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 61.2x.
What is Hims & Hers Health, Inc.'s ROE?
Hims & Hers Health, Inc.'s return on equity (ROE) is 25.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.2%.
Is HIMS stock overvalued?
Based on historical data, Hims & Hers Health, Inc. is trading at a P/E of 52.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Hims & Hers Health, Inc.'s profit margins?
Hims & Hers Health, Inc. has 59.3% gross margin and 5.2% operating margin.
How much debt does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc.'s Debt/EBITDA ratio is 6.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.